The future of the global cancer gene therapy market looks promising with opportunities in the hospital, biopharmaceutical company, and research institute markets. The global cancer gene therapy market is expected to reach an estimated $7.4 billion by 2030 with a CAGR of 17.4% from 2024 to 2030. The major drivers for this market are increasing demand for gene therapy, advance technological development in cancer treatment and daignosis, and growing incidence of cancer cases.
Some of the key questions
answered in this exclusive report are:
Q.1. What are some of
the most promising, high-growth opportunities for the cancer gene therapy
market by therapy (oncolytic virotherapy, gene induced immunotherapy, gene
transfer, and others), indication (breast cancer, ovarian cancer, liver cancer,
pancreatic cancer, lung cancer, and others), end use (hospitals,
biopharmaceutical companies, research institutes, and others), and region
(North America, Europe, Asia Pacific, and the Rest of the World)?
Q.2. Which segments will
grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and
why?
Q.4. What are the key
factors affecting market dynamics? What are the key challenges and business
risks in this market?
Q.5. What are the
business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market
and the reasons behind them?
Q.7. What are some of
the changing demands of customers in the market?
Q.8. What are the new
developments in the market? Which companies are leading these developments?
Q.9. Who are the major
players in this market? What strategic initiatives are key players pursuing for
business growth?
Q.10. What are some of
the competing products in this market and how big of a threat do they pose for
loss of market share by material or product substitution?
Q.11. What M&A
activity has occurred in the last 5 years and what has its impact been on the
industry?
Market Segmentation:
In this market,
oncolytic virotherapy, gene induced immunotherapy, and gene transfer are the
major segments of cancer gene therapy market by therapy. Lucintel forecasts
that gene induced immunotherapy will remain the largest sgement over the
forecast period due to increasing research & development activities to
lower the proliferation of cancer.Within this market, biopharmaceutical
companies will remain the largest segment due to increasing prevelance of
cancer and growing adoption of elemental gene therapy solutions by major
biopharmaceutical companies for designing cancer treatment regimens.
North America will
remain the largest region over the forecast period due to increasing research
funding for innovative therapeutics by government entities and the rising
demand for novel therapeutics to address the escalating number of cancer cases
in the region.
Abeona Therapeutics,
Asklepios Biopharmaceutical, Altor Bioscience, Bluebird Bio, Biocancell,
Celgene, Elevate Bio, Glaxosmithkline, Genelux, and Genvec are the major
suppliers in the cancer gene therapy market.
About
Lucintel
Lucintel, the premier global
management consulting and market research firm, creates winning strategies for
growth. It offers market assessments, competitive analysis, opportunity
analysis, growth
consulting, M&A, and due diligence services to executives and
key decision-makers in a variety of industries.
Contact:
Roy Almaguer
Lucintel
Dallas, Texas, USA
Email: roy.almaguer@lucintel.com
Tel. 972.636.5056
Related Reports
1. Pharmaceutical Contract Manufacturing Market
3. Stent Market
5. 3D
Printing Medical Device Market
8. Medical Lifting Sling
Market
10. Stretcher Market
No comments:
Post a Comment